Browse drugs

… Adverse events were almost exclusively in Arm 3, attributed to nivolumab. One patient achieved MRD (Arm 2), and three patients had an RC…

…CD16+/CD137+) at 1 week after the first infusion, regardless of W0180 dose (online supplemental figure S7).Of the pro-inflammatory cy…

…-mediated mechanism, most likely as an immune-related effect of ipilimumab and nivolumab.…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…ted 76 164 life years gained. Only three accelerated approvals (nivolumab to treat melanoma, pembrolizumab to treat non-small cell lung c…

… followed by rela/nivo (arm B, N=71), and anti-PD-1 followed by rela/nivo (arm C, N=79). The study assessed the impact of treatment seque…

…c MGMT-deficient G1/G2 PanNET treated with TMZ, with or without capecitabine, reportedly experienced histological progression to G3 disease …

…hemotherapy (HR=2.35; 95% CI:1.39–3.96) or pembrolizumab versus nivolumab (HR=2.46; 95%CI:1.13–5.36) ( figure 1) also conferred a higher …

…arms (n=8,684 patients) with anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, cemiplimab) for adult soli…

…77.0412Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J M…

…8.9% were male and 51.1% were female. The most common ICIs were Pembrolizumab (16276, 45.38%), Nivolumab (10548, 29.41%), Ipilimumab (3120, 8…

…mmer R, Butler MO, Hill AG, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Me…